Furthermore, whether inhibition of resistin with antiresistin RNA oligo ameliorates HFD-induced metabolic syndrome and NAFLD and the possible molecular mechanisms were investigated. The gene discussed is RETN; the disease is metabolic dysfunction-associated steatotic liver disease.